Elicio Therapeutics (ELTX)

Executive Summary

Elicio Therapeutics is a clinical-stage biotechnology company pioneering lymph node-targeted immunotherapies for aggressive solid tumors. Its proprietary Amphiphile (AMP) platform enables direct delivery of cancer antigens and immunomodulators to the lymph nodes, aiming to generate potent and durable T-cell responses. This approach seeks to overcome limitations of conventional immunotherapies by enhancing immune activation at the site where adaptive immunity is orchestrated. The company's lead indication is pancreatic ductal adenocarcinoma (PDAC), one of the most lethal cancers with high unmet need. Elicio went public in 2022 and is headquartered in Cambridge, Massachusetts. Elicio's lead candidate, ELI-002, is a lymph node-targeted cancer vaccine targeting KRAS mutations, which are prevalent in PDAC. The company recently reported positive interim Phase 1/2 data showing robust T-cell responses and encouraging survival trends. With a strong mechanistic rationale and early clinical validation, ELI-002 is poised to advance into pivotal trials. The AMP platform also holds potential for expansion into other KRAS-driven cancers and combination therapies. Elicio represents a promising investment opportunity in the immunotherapy space, with a focused strategy and a novel delivery technology that could improve outcomes for patients with hard-to-treat cancers.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 data update for ELI-002 in pancreatic cancer20% success
• Q1 2027Initiation of pivotal Phase 2/3 trial for ELI-00230% success
• Q2 2027Partnership or licensing deal for AMP platform in additional indications15% success